Pfizer, a leading MNC, has posted satisfactory growth in profits level during the fourth quarter ended March 2013 despite stagnant sales. Its net profit increased by 20.9 per cent to Rs. 58.16 crore from Rs. 48.10 crore in the corresponding period of last year. Its net sales improved only by 0.2 per cent to Rs. 252.19 crore from Rs. 251.74 crore. Its EBDITA improved by 13.4 per cent to Rs. 85.35 crore mainly due to higher other operating income which went up by 41 per cent to Rs. 29.55 crore.

The company declared equity dividend of 125 per cent as well as a special dividend of 200 per cent for the year 2012-13 on account of sale of animal health business aggregating to total dividend of 32.50 per  equity share (325%) of Rs 10 each..

For the full year ended March 2013, its net profit jumped by 173 per cent to Rs. 503.20 crore from Rs. 184.61 crore mainly on account of gain on sale of Animal health business and sale of investments. The company received Rs. 382.52 crore from sale of animal health business and Rs. 31.60 crore from sales of investments as against nil in the previous year. Otherwise its EBDITA improved only by 1.5 per cent to Rs. 292.33 crore from Rs. 288.06 crore in the previous year.

Its net sales declined by 6.8 per cent during the year ended March 2013 to Rs. 947.98 crore from Rs. 1017.32 crore on account of divestment of animal health business. Its pharmaceutical sales improved by 3.5 per cent to Rs. 915.06 crore as compared to Rs. 883.85 crore in the previous year. During 2011-12, Pfizer reported sales of Rs. 133.47 crore from animal health business and Rs. 75.07 crore from services.